These insights are highly relevant to contemporary treatment strategies, particularly in light of emerging evidence supporting the addition of CDK4/6 inhibitors to address hormone resistance in ER+/HER2+ breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.